WO1998040069A3 - Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations - Google Patents

Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations Download PDF

Info

Publication number
WO1998040069A3
WO1998040069A3 PCT/EP1998/001478 EP9801478W WO9840069A3 WO 1998040069 A3 WO1998040069 A3 WO 1998040069A3 EP 9801478 W EP9801478 W EP 9801478W WO 9840069 A3 WO9840069 A3 WO 9840069A3
Authority
WO
WIPO (PCT)
Prior art keywords
stabilization
amino acid
acid
cyclodextrin
cyclodextrin combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/001478
Other languages
French (fr)
Other versions
WO1998040069A2 (en
Inventor
Karin Klokkers
Marion Kutschera
Wilfried Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexal AG
Original Assignee
Hexal AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8226585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998040069(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU72070/98A priority Critical patent/AU731186B2/en
Priority claimed from EP98919099.6A external-priority patent/EP0991407B2/en
Priority to JP53923798A priority patent/JP4608031B2/en
Priority to DK98919099T priority patent/DK0991407T4/en
Priority to SI9830069T priority patent/SI0991407T2/en
Priority to PL335571A priority patent/PL191570B1/en
Priority to HU0002364A priority patent/HU225587B1/en
Priority to IL13165198A priority patent/IL131651A0/en
Priority to HK00103624.8A priority patent/HK1024182B/en
Priority to SK1209-99A priority patent/SK284811B6/en
Priority to DE69802688T priority patent/DE69802688T3/en
Application filed by Hexal AG filed Critical Hexal AG
Priority to EP98919099.6A priority patent/EP0991407B2/en
Priority to BR9808581-6A priority patent/BR9808581A/en
Priority to CA002282513A priority patent/CA2282513C/en
Priority to KR1019997008327A priority patent/KR100563764B1/en
Priority to NZ337592A priority patent/NZ337592A/en
Priority to US09/319,895 priority patent/US6248758B1/en
Priority to PCT/EP1998/001478 priority patent/WO1998040069A2/en
Priority to AT98919099T priority patent/ATE209491T1/en
Publication of WO1998040069A2 publication Critical patent/WO1998040069A2/en
Publication of WO1998040069A3 publication Critical patent/WO1998040069A3/en
Priority to NO19994409A priority patent/NO327212B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A pharmaceutical formulation comprising or consisting of: a benzimidazole derivative as active ingredient, and as excipients, at least one cyclodextrin and at least one amino acid.
PCT/EP1998/001478 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations Ceased WO1998040069A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
PCT/EP1998/001478 WO1998040069A2 (en) 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
EP98919099.6A EP0991407B2 (en) 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazols with amino/cyclodextrin combinations
JP53923798A JP4608031B2 (en) 1997-03-13 1998-03-13 Stabilization of acid-sensitive benzimidazoles by amino acid / cyclodextrin mixtures
DK98919099T DK0991407T4 (en) 1997-03-13 1998-03-13 Stabilization of acid-sensitive benzimidazoles by amino / cyclodextrin combinations
SI9830069T SI0991407T2 (en) 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazols with amino/cyclodextrin combinations
PL335571A PL191570B1 (en) 1997-03-13 1998-03-13 Stabilisation of acid-sensitive benzimidazoles by combining them with amino acids and cyclodextrins
HU0002364A HU225587B1 (en) 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
IL13165198A IL131651A0 (en) 1997-03-13 1998-03-13 A pharmaceutical formulation containing benzimidazoles with amino acid/caclodextrin combinations and a process for producing the same
HK00103624.8A HK1024182B (en) 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
SK1209-99A SK284811B6 (en) 1997-03-13 1998-03-13 Pharmaceutical formulation and method of its preparation
DE69802688T DE69802688T3 (en) 1997-03-13 1998-03-13 STABILIZATION OF ACID SULFUR BENZIMIDAZOLES USING AMINO ACID / CYCLODEXTRIN COMBINATIONS
AU72070/98A AU731186B2 (en) 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
CA002282513A CA2282513C (en) 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
AT98919099T ATE209491T1 (en) 1997-03-13 1998-03-13 STABILIZATION OF ACID SENSITIVITY BENZIMIDAZOLES USING AMINO ACID/CYCLODEXTRIN COMBINATIONS
BR9808581-6A BR9808581A (en) 1997-03-13 1998-03-13 Stabilization of acid-sensitive benzimidazoles with amino acid / cyclodextrin combinations
KR1019997008327A KR100563764B1 (en) 1997-03-13 1998-03-13 Method for stabilizing acid sensitive benzimidazoles by using amino acids and cyclodextrins in combination
NZ337592A NZ337592A (en) 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazoles with amino/cyclodextrin combinations
US09/319,895 US6248758B1 (en) 1997-03-13 1998-03-13 Pharmaceutical antacid
NO19994409A NO327212B1 (en) 1997-03-13 1999-09-10 Pharmaceutical formulation comprising benzimidazoles and amino acid / cyclodextrin combinations as well as processes for their preparation.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97104200.7 1997-03-13
EP97104200 1997-03-13
PCT/EP1998/001478 WO1998040069A2 (en) 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
EP98919099.6A EP0991407B2 (en) 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazols with amino/cyclodextrin combinations

Publications (2)

Publication Number Publication Date
WO1998040069A2 WO1998040069A2 (en) 1998-09-17
WO1998040069A3 true WO1998040069A3 (en) 1998-12-17

Family

ID=8226585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001478 Ceased WO1998040069A2 (en) 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations

Country Status (23)

Country Link
US (1) US6248758B1 (en)
JP (1) JP4608031B2 (en)
KR (1) KR100563764B1 (en)
CN (1) CN1113649C (en)
AT (1) ATE209491T1 (en)
AU (1) AU731186B2 (en)
BR (1) BR9808581A (en)
CA (1) CA2282513C (en)
CZ (1) CZ291842B6 (en)
DE (1) DE69802688T3 (en)
DK (1) DK0991407T4 (en)
ES (1) ES2167891T5 (en)
HU (1) HU225587B1 (en)
IL (1) IL131651A0 (en)
NO (1) NO327212B1 (en)
NZ (1) NZ337592A (en)
PL (1) PL191570B1 (en)
PT (1) PT991407E (en)
SI (1) SI0991407T2 (en)
SK (1) SK284811B6 (en)
TR (1) TR199902233T2 (en)
WO (1) WO1998040069A2 (en)
ZA (1) ZA982155B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005008412A1 (en) 2005-02-24 2006-09-07 Ratiopharm Gmbh New piperazine salt of omeprazol is proton pump inhibitor useful to prevent/treat e.g. peptic ulcer, gastritis, gastroesophageal reflux, acute stress ulcer or dyspepsia

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JP4127740B2 (en) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 Stabilized benzimidazole compound-containing composition
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
PT1018340E (en) * 1999-01-06 2003-12-31 Tecnimede Sociedade Tecnico Medicinal Sa INCLUSION COMPLEXES OF AMINO ACID SALTS OF BENZIMIDAZOLE DERIVATIVES WITH CYCLLODEXTRINS, ITS PREPARATION AND PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
DE19959419A1 (en) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stable pharmaceutical preparations comprising a benzimidazole and process for their preparation
CN1322850C (en) * 2000-06-02 2007-06-27 沈阳药科大学 Nicardipine hydro-chloride powder injection and its preparing method
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
KR100612398B1 (en) * 2000-11-14 2006-08-16 바이탈 헬스 사이언시즈 피티와이 리미티드 Complexes of phosphate derivatives
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
AU2002317053B2 (en) * 2001-07-27 2004-08-05 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
GB2379854B (en) * 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
BR0215102A (en) * 2001-12-13 2004-11-03 Vital Health Sciences Pty Ltd Transdermal transport of compounds, topical formulation, method for improving skin absorption, method for hormone replacement therapy, use of one or more phosphate derivatives of a pharmaceutical hydroxy compound in a transdermal application system, transdermal application system, method for application of a pharmaceutical hydroxy compound to an individual and to improve the effectiveness of a
EP1467770A1 (en) * 2002-01-15 2004-10-20 ALTANA Pharma AG Pantoprazole cyclodextrin inclusion complexes
ITMI20021074A1 (en) * 2002-05-20 2003-11-20 Actimex S R L TERNARY COMPOSITION INCLUDING AN ACTIVE SUBSTANCE AND COMMUNICATION PROCESS FOR ITS PREPARATION
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US7732474B2 (en) * 2002-08-02 2010-06-08 Ratiopharm, Gmbh Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ITMI20022549A1 (en) * 2002-12-02 2004-06-03 Actimex S R L QUATERNARY COMPOSITION INCLUDING PROPOLIS AS AN ACTIVE SUBSTANCE.
US20040109920A1 (en) * 2002-12-04 2004-06-10 Bioactives Llc Coated carotenoid cyclodextrin complexes
BRPI0406484A (en) * 2003-01-17 2005-12-06 Vital Health Sciences Pty Ltd Method of inhibiting the occurrence of one or more of the following conditions: monocyte / macrophage proliferation; or the proliferation of smooth muscle cells; or the expression of cd36 receptors; or the absorption of low-density lipoprotein - oxidized ldl, method of relief of symptoms of treatment or prevention of atherosclerosis; diabetes; alzheimer's disease, method of inhibiting the occurrence of plaque formation in the vascular system, method of relieving inflammation associated with the occurrence of one or more of the following conditions: the proliferation of monocytes, the proliferation of smooth muscle cells, the expression oxidized ldl or decontaminating receptor, pharmaceutical composition, use of an effective amount of one or more derivatives or phosphate of one or more electron transfer agents together with a suitable vehicle or diluent, use of an effective amount of one or more (alpha) -tocopherol phosphate derivatives together with an appropriate vehicle or diluent and use of an effective amount of one or more phosphate derivatives from one or more electron transfer agents selected from the group consisting of mono-tocopheryl phosphate, di-tocopheryl phosphate and mixtures of these together with a suitable vehicle or diluent
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2557354C (en) 2004-03-03 2013-05-07 Vital Health Sciences Pty Ltd. Alkaloid formulations
KR20050105565A (en) * 2004-04-30 2005-11-04 에스케이케미칼주식회사 Stable pharmaceutical composition containing benzimidazole compounds and method of manufacturing the same
WO2005112637A1 (en) * 2004-05-14 2005-12-01 Decode Chemistry, Inc. Formulations for non-parenteral use including hydrophobic cyclodextrins
US20060058276A1 (en) * 2004-07-15 2006-03-16 Oded Friedman Processes for the preparation and purification of rocuronium bromide
JP5198858B2 (en) * 2004-08-03 2013-05-15 バイタル ヘルス サイエンシズ プロプライアタリー リミティド Carrier for enteral administration
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
MX2007015949A (en) 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof.
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
WO2007070981A1 (en) * 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd Compounds having cytokine modulating properties
CN102838599A (en) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 Polymorphs
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US7840305B2 (en) 2006-06-28 2010-11-23 3M Innovative Properties Company Abrasive articles, CMP monitoring system and method
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (en) 2008-04-03 2009-12-10 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
US20110038933A1 (en) 2008-05-06 2011-02-17 Dexcell Ltd. Stable benzimidazole formulation
PE20100156A1 (en) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int NAFLD TREATMENT
AU2009267145A1 (en) * 2008-06-30 2010-01-07 Merck Sharp & Dohme Corp. Solid dosage formulations of telcagepant potassium
KR20200118243A (en) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
MX370599B (en) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases.
BRPI0919288A2 (en) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh combination therapy for treatment of diabetes and related conditions.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (en) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх SALT FORMS OF ORGANIC COMPOUND
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
JP5806287B2 (en) 2010-03-30 2015-11-10 フォスファジェニクス リミティド Transdermal delivery patch
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
CN102584633B (en) * 2011-12-16 2013-07-03 山东大学 Lysine alpha-amino carbobenzoxy high-efficiency selective protection method and product thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (en) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Medical use of a DPP-4 inhibitor
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US20190105274A1 (en) * 2015-07-13 2019-04-11 Kyowa Hakko Bio Co., Ltd. Tablets containing arginine at high concentration
MX383940B (en) 2015-12-09 2025-03-14 Phosphagenics Ltd Pharmaceutical formulation
CN106924179B (en) * 2015-12-29 2021-04-30 成都康弘药业集团股份有限公司 Liquid preparation containing Vonoprazan fumarate and preparation method thereof
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR101829685B1 (en) * 2016-07-28 2018-02-19 씨제이헬스케어 주식회사 Composition for injection having improved solubility and stability
KR101829705B1 (en) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 Composition for injection having improved stability
JP7198754B2 (en) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド Method
CN108324957B (en) * 2018-04-20 2021-04-13 广州白云山医药集团股份有限公司白云山制药总厂 S-carboxymethyl-L-cysteine inclusion compound and enteric preparation composition thereof
CN116585283B (en) * 2023-05-26 2024-11-22 桂林华信制药有限公司 Lansoprazole enteric-coated capsules and preparation method thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427787A1 (en) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz ACTIVE SUBSTANCE COMPLEXES OF 5-METHOXY-2 ((4-METHOXY-3,5-DIMETHYL-2-PYRIDYL) METHYLSULFINYL) -1H-BENZIMIDAZOLE WITH CYCLODEXTRINES, THEIR PRODUCTION AND MEDICINAL PRODUCTS
DE3427786A1 (en) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Inclusion complexes of benzimidazole derivatives with cyclodextrins, the preparation thereof, and medicaments
EP0444625A1 (en) * 1990-02-27 1991-09-04 Hanmi Pharm. Ind. Co., Ltd. Omeprazole compositions designed for administration in Rectum
KR920008161B1 (en) * 1990-02-19 1992-09-24 한미약품공업주식회사 Process for preparing omeprazole oral preparation
WO1993013138A1 (en) * 1991-12-31 1993-07-08 Sunkyong Industries Co., Ltd. A method for preparing enteric-coated oral drugs containing acid-unstable compounds
JPH05194225A (en) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd Stabilized anti-ulcer drug-containing preparation
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
WO1996024338A1 (en) * 1995-02-09 1996-08-15 Astra Aktiebolag New pharmaceutical formulation and process
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CZ289804B6 (en) * 1994-07-08 2002-04-17 Astrazeneca Ab Multiple units tableted dosage form
JPH0948730A (en) * 1995-06-02 1997-02-18 Takeda Chem Ind Ltd Stabilizer composition containing benzimidazole-based anti-ulcer agent having improved water solubility

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427787A1 (en) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz ACTIVE SUBSTANCE COMPLEXES OF 5-METHOXY-2 ((4-METHOXY-3,5-DIMETHYL-2-PYRIDYL) METHYLSULFINYL) -1H-BENZIMIDAZOLE WITH CYCLODEXTRINES, THEIR PRODUCTION AND MEDICINAL PRODUCTS
DE3427786A1 (en) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Inclusion complexes of benzimidazole derivatives with cyclodextrins, the preparation thereof, and medicaments
KR920008161B1 (en) * 1990-02-19 1992-09-24 한미약품공업주식회사 Process for preparing omeprazole oral preparation
EP0444625A1 (en) * 1990-02-27 1991-09-04 Hanmi Pharm. Ind. Co., Ltd. Omeprazole compositions designed for administration in Rectum
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
JPH05194225A (en) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd Stabilized anti-ulcer drug-containing preparation
WO1993013138A1 (en) * 1991-12-31 1993-07-08 Sunkyong Industries Co., Ltd. A method for preparing enteric-coated oral drugs containing acid-unstable compounds
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
WO1996024338A1 (en) * 1995-02-09 1996-08-15 Astra Aktiebolag New pharmaceutical formulation and process
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 119, no. 22, 29 November 1993, Columbus, Ohio, US; abstract no. 234039, XP002079803 *
CHEMICAL ABSTRACTS, vol. 124, no. 16, 15 April 1996, Columbus, Ohio, US; abstract no. 211738, XP002079802 *
DATABASE WPI Week 9332, Derwent World Patents Index; AN 93-255964 [32], XP002079804 *
S.J. HWANG ET AL.: "A COMPARATIVE STUDY ON THE PHARMACEUTICAL PROPERTIES OF RECTAL SUPPOSITORY CONTAINING OMEPRAZOLE COMPLEXES", YAKCHE HAKHOECHI, vol. 25, no. 3, 1995, pages 227 - 237 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005008412A1 (en) 2005-02-24 2006-09-07 Ratiopharm Gmbh New piperazine salt of omeprazol is proton pump inhibitor useful to prevent/treat e.g. peptic ulcer, gastritis, gastroesophageal reflux, acute stress ulcer or dyspepsia

Also Published As

Publication number Publication date
SK120999A3 (en) 2000-09-12
HUP0002364A3 (en) 2001-12-28
WO1998040069A2 (en) 1998-09-17
KR20000076232A (en) 2000-12-26
HUP0002364A2 (en) 2000-12-28
JP2001518083A (en) 2001-10-09
SI0991407T2 (en) 2005-10-31
CZ291842B6 (en) 2003-06-18
ZA982155B (en) 1998-12-01
CZ312899A3 (en) 2000-02-16
DK0991407T3 (en) 2002-03-25
SI0991407T1 (en) 2002-04-30
HK1024182A1 (en) 2000-10-05
HU225587B1 (en) 2007-03-28
CA2282513A1 (en) 1998-09-17
PL191570B1 (en) 2006-06-30
TR199902233T2 (en) 1999-12-21
DE69802688D1 (en) 2002-01-10
NO994409D0 (en) 1999-09-10
AU7207098A (en) 1998-09-29
PL335571A1 (en) 2000-05-08
US6248758B1 (en) 2001-06-19
ATE209491T1 (en) 2001-12-15
DE69802688T3 (en) 2006-01-26
KR100563764B1 (en) 2006-03-24
DK0991407T4 (en) 2005-08-08
ES2167891T3 (en) 2002-05-16
AU731186B2 (en) 2001-03-29
CN1250372A (en) 2000-04-12
EP0991407A2 (en) 2000-04-12
DE69802688T2 (en) 2002-08-01
ES2167891T5 (en) 2005-11-16
NO994409L (en) 1999-10-21
NZ337592A (en) 2001-01-26
NO327212B1 (en) 2009-05-11
SK284811B6 (en) 2005-12-01
JP4608031B2 (en) 2011-01-05
EP0991407B9 (en) 2002-11-13
IL131651A0 (en) 2001-01-28
EP0991407B1 (en) 2001-11-28
CN1113649C (en) 2003-07-09
PT991407E (en) 2002-05-31
CA2282513C (en) 2007-09-18
BR9808581A (en) 2000-05-30

Similar Documents

Publication Publication Date Title
CA2282513A1 (en) Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
AU3076700A (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
EP1589947B8 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
WO2000041681A3 (en) MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
DK1169024T3 (en) Pregelatinized starch in a controlled release formulation
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
AU2001278772A1 (en) Benzoic acid derivatives and drugs containing the same as the active ingredient
CA2352915A1 (en) Pharmaceutical compositions containing mupirocin
AR012868A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN LHRH AGONIST PEPTIDE, AN LHRH ANTAGONIST, OR A GRF AND NICOTINAMIDE PEPTIDE.
AU5647199A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AU5443499A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
CA2385867A1 (en) Sustained release form comprising alpha-lipoic acid or derivatives thereof
AU2023801A (en) Dihalopropenyloxybenzene derivatives and pesticides containing the same as the active ingredient
AU1556601A (en) 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient
AU2827500A (en) Fluorinated chalcone derivatives or salts thereof and drugs containing the same as the active ingredient
ES2130069A1 (en) Pharmaceutical preparation with delayed release of active ingredient
HK1088213A (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
AU2002309047A1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU2002355691A1 (en) Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient
ECSP993104A (en) NEW ORAL FORMULATION

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131651

Country of ref document: IL

Ref document number: 98803296.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2282513

Country of ref document: CA

Ref document number: 2282513

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 337592

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV1999-3128

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 120999

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 09319895

Country of ref document: US

ENP Entry into the national phase

Ref document number: 1998 539237

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/008374

Country of ref document: MX

Ref document number: 1998919099

Country of ref document: EP

Ref document number: 72070/98

Country of ref document: AU

Ref document number: 1019997008327

Country of ref document: KR

Ref document number: 1999/02233

Country of ref document: TR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1999-3128

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1998919099

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997008327

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 72070/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998919099

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV1999-3128

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1019997008327

Country of ref document: KR